Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 227-234

  Zhang, Qian ^a   Zhang, Lian ^a   Li, LiLi ^b   Wang, Zhaohui ^b   Ying, Jianming ^c   Fan, Yu ^a   Xu, Ben ^a   Wang, Lu ^a   Liu, Qianling ^a   Chen, Guangfu ^d   Tao, Qian ^b   Jin, Jie ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Epigenetic; IRF8; Methylation; Renal carcinoma; Tumor suppressor

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P21; SURVIVIN; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INTERFERON REGULATORY FACTOR; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CARCINOGENESIS; CASP1 GENE; CELL MIGRATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; MALE; P21 GENE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PTEN GENE; RENAL CELL CARCINOMA CELL LINE; SURVIVIN GENE; YAP1 GENE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; DOWN REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; KIDNEY TUMOR; M PHASE CELL CYCLE CHECKPOINT; PATHOLOGY; PROGNOSIS; PROMOTER REGION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

AZACITIDINE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOWN-REGULATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTERFERON REGULATORY FACTORS; KIDNEY NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; MALE; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84908010846     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.040     Document Type: Article

References (38)

1. Vincenzi B., Santini D., Tonini G. Renal-cell carcinoma. N. Engl. J. Med 2006, 354:1095-1096. Author reply 1095-1096.
2. Cancer N. Genome Atlas Research, Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
3. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet 2002, 3:415-428.
4. Knudson A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 2001, 1:157-162.
5. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
6. Yao M., Yoshida M., Kishida T., Nakaigawa N., Baba M., Kobayashi K., et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst 2002, 94:1569-1575.
7. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
8. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. U.S.A. 1994, 91:9700-9704.
9. Morrissey C., Martinez A., Zatyka M., Agathanggelou A., Honorio S., Astuti D., et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001, 61:7277-7281.
10. Dahl E., Wiesmann F., Woenckhaus M., Stoehr R., Wild P.J., Veeck J., et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene 2007, 26:5680-5691.
11. Ricketts C., Zeegers M.P., Lubinski J., Maher E.R. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS ONE 2009, 4:e6037.
12. Sanz-Casla M.T., Maestro M.L., del Barco V., Zanna I., Moreno J., Vidaurreta M., et al. Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol. Res 2003, 31:159-162.
13. Jin H., Wang X., Ying J., Wong A.H., Cui Y., Srivastava G., et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc. Natl Acad. Sci. U.S.A. 2007, 104:12353-12358.
14. Zhang Q., Ying J., Li J., Fan Y., Poon F.F., Ng K.M., et al. Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage. J. Urol 2010, 184:731-737.
15. Zhang Q., Ying J., Zhang K., Li H., Ng K.M., Zhao Y., et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett 2007, 249:220-226.
16. Nguyen H., Hiscott J., Pitha P.M. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997, 8:293-312.
17. Tamura T., Ozato K. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J. Interferon Cytokine Res 2002, 22:145-152.
18. Takaoka A., Tamura T., Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 2008, 99:467-478.
19. Sato M., Taniguchi T., Tanaka N. The interferon system and interferon regulatory factor transcription factors - studies from gene knockout mice. Cytokine Growth Factor Rev 2001, 12:133-142.
20. Gabriele L., Phung J., Fukumoto J., Segal D., Wang I.M., Giannakakou P., et al. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J. Exp. Med 1999, 190:411-421.
21. Taniguchi T., Ogasawara K., Takaoka A., Tanaka N. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol 2001, 19:623-655.
22. Lee K.Y., Geng H., Ng K.M., Yu J., van Hasselt A., Cao Y., et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 2008, 27:5267-5276.
23. Meraro D., Hashmueli S., Koren B., Azriel A., Oumard A., Kirchhoff S., et al. Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J. Immunol 1999, 163:6468-6478.
24. Hu X., Yang D., Zimmerman M., Liu F., Yang J., Kannan S., et al. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res 2011, 71:2882-2891.
25. Konieczna I., Horvath E., Wang H., Lindsey S., Saberwal G., Bei L., et al. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J. Clin. Invest 2008, 118:853-867.
26. Vidovic K., Svensson E., Nilsson B., Thuresson B., Olofsson T., Lennartsson A., et al. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia 2010, 24:992-1000.
27. McGough J.M., Yang D., Huang S., Georgi D., Hewitt S.M., Rocken C., et al. DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. Molecul. Cancer Res 2008, 6:1841-1851.
28. Yang D., Thangaraju M., Browning D.D., Dong Z., Korchin B., Lev D.C., et al. IFN regulatory factor 8 mediates apoptosis in nonhemopoietic tumor cells via regulation of Fas expression. J. Immunol 2007, 179:4775-4782.
29. Yamashita M., Toyota M., Suzuki H., Nojima M., Yamamoto E., Kamimae S., et al. DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. Cancer Sci 2010, 101:1708-1716.
30. Tshuikina M., Jernberg-Wiklund H., Nilsson K., Oberg F. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Exp. Hematol 2008, 36:1673-1681.
31. Banik D., Khan A.N., Walseng E., Segal B.H., Abrams S.I. Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity. PLoS ONE 2012, 7:e45422.
32. Li P., Wong J.J., Sum C., Sin W.X., Ng K.Q., Koh M.B., et al. IRF8 and IRF3 cooperatively regulate rapid interferon-beta induction in human blood monocytes. Blood 2011, 117:2847-2854.
33. Greenbaum D., Colangelo C., Williams K., Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003, 4:117.
34. Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet 2012, 13:227-232.
35. Yang D., Wang S., Brooks C., Dong Z., Schoenlein P.V., Kumar V., et al. IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res 2009, 69:1080-1088.
36. Shen C., Gu M., Song C., Miao L., Hu L., Liang D., et al. The tumorigenicity diversification in human embryonic kidney 293 cell line cultured in vitro. Biologicals 2008, 36:263-268.
37. Yang D., Thangaraju M., Greeneltch K., Browning D.D., Schoenlein P.V., Tamura T., et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 2007, 67:3301-3309.
38. Yang J., Hu X., Zimmerman M., Torres C.M., Yang D., Smith S.B., et al. Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells. J. Immunol 2011, 187:4426-4430.